Search Results
40 items found for "Pina M Cardarelli"
- Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast
Pina Cardarelli, CSO of GPCR Therapeutics.
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Devki D Sukhtankar and Pina M Cardarelli's research: Burixafor Hydrobromide (GPC-100) effects on hematopoietic
- Disentangling bias between G q, GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine
G protein-coupled receptors (GPCRs) transmit extracellular signals to the inside by activation of intracellular effector proteins. Different agonists can promote differential receptor-induced signaling responses - termed bias - potentially by eliciting different levels of recruitment of effector proteins. As activation and recruitment of effector proteins might influence each other, thorough analysis of bias is difficult. Here, we compared the efficacy of seven agonists to induce G protein, G protein-coupled receptor kinase 2 (GRK2), as well as arrestin3 binding to the muscarinic acetylcholine receptor M3 by utilizing FRET-based assays. In order to avoid interference between these interactions, we studied GRK2 binding in the presence of inhibitors of Gi and Gq proteins and analyzed arrestin3 binding to prestimulated M3 receptors to avoid differences in receptor phosphorylation influencing arrestin recruitment. We measured substantial differences in the agonist efficacies to induce M3R-arrestin3 versus M3R-GRK2 interaction. However, the rank order of the agonists for G protein- and GRK2-M3R interaction was the same, suggesting that G protein and GRK2 binding to M3R requires similar receptor conformations, whereas requirements for arrestin3 binding to M3R are distinct. Read full article
- 📰 GPCR Weekly News, May 1 to 7, 2023
Expectations, EPS Lags “As Precision Medicine is critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics Trevena to Participate in Three Upcoming Conferences
- 📰 GPCR Weekly News, February 20 to 26, 2023
Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics
- Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery
M., & Fields, S. (2014). Deep mutational scanning: a new style of protein science. M., Marti-Solano, M., Sandhu, M., Kobilka, B. K., Bouvier, M., & Babu, M. M. (2023). Kosar, M., Sarott, R. C., Sykes, D. A., Viray, A. E., Vitale, R. M., Tomašević, N., ... & Carreira, E. M. (2024). M., Christopoulos, A., & May, L. T. (2016).
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
M., Marti-Solano, M., Sandhu, M., Kobilka, B. K., Bouvier, M., & Babu, M. M. (2023). Howard, M. K., Hoppe, N., Huang, X. P., Macdonald, C. B., Mehrota, E., Grimes, P.
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
., Vieira-Rocha, M. S., Vojtek, M., Sousa, J. B., & Diniz, C. (2021). E., Healy, M. D., & Collins, B. M. (2019). Academy of Sciences of the United States of America, 100(19), 10782–10787. https://doi.org/10.1073/pnas B., Conti, M., & von Zastrow, M. (2017). M., & Murray, F. (2018).
- From DNA day to GPCR genomics
., Bolanowski, M. A., Bennett, C. D., Rands, E., Diehl, R. E., Mumford, R. A., Slater, E. S., Caron, M. G., Lefkowitz, R. J., & Strader, C. D. (1986). Nature, 321(6065), 75–79. https://doi.org/10.1038/321075a0 Fredriksson, R., Lagerström, M. M., Pérez-Hernández, G., Batebi, H., Gao, Y., Eskici, G., Seven, A. ., Casiraghi, M., He, F., Maul, L., Gmeiner, P., Kobilka, B. K., Hildebrand, P.
- Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation
M., Medel-Lacruz, B., Baidya, M., Makarova, M., Mistry, R., Goulding, J., Drube, J., Hoffmann, C., Owen M., Shukla, A. K., Selent, J., Hill, S. J., & Calebiro, D. (2023). M., Kawakami, K., Masureel, M., Maeda, S., Garcia, K. C., von Zastrow, M., Inoue, A., & Kobilka, B. I., & von Zastrow, M. (2001).
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
A recent breakthrough study published in Nature by Makaía M. Papasergi-Scott, M. M. et al. Time-resolved cryo-EM of G-protein activation by a GPCR.
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
approach to this problem by predicting potential resistance mutations before they are clinically observed (Pines M. (2011). Deep mutational scanning: assessing protein function on a massive scale. M., Stephany, J. J., & Fields, S. (2014). M., Trinidad, D. D., English, J. G., Coyote-Maestas, W., & Aashish Manglik. (2024). BioRxiv (Cold Spring Harbor Laboratory) . https://doi.org/10.1101/2024.04.17.590000 Pines, G., Fankhauser
- Nanobodies: New Dimensions in GPCR Signaling Research
., Radwanska, M., & Magez, S. (2023). M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. M., Dukkipati, A., Feinberg, E. N., Angelini, A., Waghray, D., Dror, R. O., Ploegh, H.
- The sixth transmembrane region of a pheromone G-protein coupled receptor, Map3, is implicated in ...
The fission yeast Schizosaccharomyces pombe has two mating types, Plus (P) and Minus (M). investigated the stringency of the two GPCRs, Mam2 and Map3, for their respective pheromones, P-factor and M-factor acid residues of Map3, F214 and F215, are key residues important for discrimination of closely related M-factors
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
M. Aragay et al. 1998). Removal of G proteins by using CRISPR KO of Gαi (Gαi KO) or KO of all Gα subtypes (Gα_all KO) (M. constitutively internalize through clathrin-coated pits independently of phosphorylation and β-arrestin (M. M. Paing et al. 2022; J. L. Sapmaz et al. 2019, M. N. J. Seaman 2012).
- Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery
M. et al. 2018; Manglik, A. et al. 2012). the formation of dimers and alter their function by destroying the interface between two receptors (M. structure of CB1R–5HT2AR heterodimers, preventing cognitive impairment while preserving analgesia in vivo (M.
- Decoding β-Arrestins: from Structure to function
H. 2020, Casiraghi, M. et al. 2019), double electron-electron resonance (DEER) spectroscopy for high-resolution M. et al. 2019), and hydrogen-deuterium exchange (HDX) mass spectrometry for time-dependent conformational M. et al. 1999), while dual knockout is lethal (Schmid, C. L., & Bohn, L. M. 2009).
- 📰 GPCR Weekly News, December 18 to 31, 2023
Franziska M Heydenreich, Michel Bouvier, Brian Kobilka, M Madan Babu, and their team's work on Molecular
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
David Reiner-Link , Alessandro Berghella , Brinda K Rana , G Enrico Rovati , Valerie Capra , Caroline M Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de Velasco , Steven H Olson , Lauren M
- Canonical chemokine receptors as scavenging “decoys”
M, et al. 2023).
- Navigating the Signaling Network: RTK and GPCR Crosstalk Uncovered
., Ghassemian, M., Kufareva, I., & Ghosh, P. (2024).
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
Bouvier, M., Oligomerization of G-protein-coupled transmitter receptors.
- 📰 GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
SMOOTHENED-PKA signaling in the Hedgehog cascade Elita Yuliantie , Arthur Christopoulos , Patrick M.
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
M., & Lefkowitz, R. J. (2003).
- 📰 GPCR Weekly News, May 8 to 14, 2023
Continuing Study Addex Therapeutics in the 23rd BioEquity Europe Conference Simon Bekker-Jensen and Mette M
- 📰 GPCR Weekly News, March 11 to 17, 2024
This week's highlight includes congrats to: Makaía M Papasergi-Scott, Peter Gmeiner, Brian K Kobilka,
- VAMP2: a crucial player in the delivery of MOR to the synapse
K ´ onigstorfer, M. Mozhayeva, Y. Sara, T.C. Südhof, and ¨ E.T. Kavalali. 2001.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Anson, M., et al., Incidence of new onset type 2 diabetes in adults living with obesity treated with